107 related articles for article (PubMed ID: 8402725)
1. Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients.
Lüthgens K; Ebert W; Trefz G; Gabrijelcic D; Turk V; Lah T
Cancer Detect Prev; 1993; 17(3):387-97. PubMed ID: 8402725
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin B, thiols and cysteine protease inhibitors in squamous-cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1997; 44(4):219-39. PubMed ID: 9473776
[TBL] [Abstract][Full Text] [Related]
3. Increased cathepsin B activity in human lung tumors.
Krepela E; Kasafírek E; Novák K; Viklický J
Neoplasma; 1990; 37(1):61-70. PubMed ID: 2320181
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors.
Rozhin J; Gomez AP; Ziegler GH; Nelson KK; Chang YS; Fong D; Onoda JM; Honn KV; Sloane BF
Cancer Res; 1990 Oct; 50(19):6278-84. PubMed ID: 2400991
[TBL] [Abstract][Full Text] [Related]
5. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients.
Werle B; Lötterle H; Schanzenbächer U; Lah TT; Kalman E; Kayser K; Bülzebruck H; Schirren J; Krasovec M; Kos J; Spiess E
Br J Cancer; 1999 Oct; 81(3):510-9. PubMed ID: 10507778
[TBL] [Abstract][Full Text] [Related]
6. [Determination of telomerase activity in BALF cells from lung cancer patients].
Chen L; Chen L; Wang N
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Dec; 21(12):730-2. PubMed ID: 11480075
[TBL] [Abstract][Full Text] [Related]
7. TNF-alpha, IL-1 and IL-6 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC).
Chyczewska E; Mróz RM; Kowal E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():123-35. PubMed ID: 9337531
[TBL] [Abstract][Full Text] [Related]
8. IL-2 concentration in bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients.
Chyczewska E; Mróz RM; Kowal E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():136-45. PubMed ID: 9337532
[TBL] [Abstract][Full Text] [Related]
9. Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases.
Lenarcic B; Gabrijelcic D; Rozman B; Drobnic-Kosorok M; Turk V
Biol Chem Hoppe Seyler; 1988 May; 369 Suppl():257-61. PubMed ID: 3264507
[TBL] [Abstract][Full Text] [Related]
10. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer.
Zore I; Krasovec M; Cimerman N; Kuhelj R; Werle B; Nielsen HJ; Brünner N; Kos J
Biol Chem; 2001 May; 382(5):805-10. PubMed ID: 11517934
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas.
Dobashi Y; Watanabe H; Sato Y; Hirashima S; Yanagawa T; Matsubara H; Ooi A
J Pathol; 2006 Dec; 210(4):431-40. PubMed ID: 17029220
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
[TBL] [Abstract][Full Text] [Related]
15. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
16. An inactive cathepsin B-like enzyme and cysteine proteinase inhibitors in colon cancer ascites.
Matsuoka Y; Tsushima H; Koga Y; Mihara H; Hopsu-Havu VK
Neoplasma; 1992; 39(2):107-14. PubMed ID: 1528307
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma.
Werle B; Kraft C; Lah TT; Kos J; Schanzenbächer U; Kayser K; Ebert W; Spiess E
Cancer; 2000 Dec; 89(11):2282-91. PubMed ID: 11147599
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence demonstration of cathepsin B-like cysteine proteinase activity in lung squamous cell carcinomas and surrounding tissues.
Kolár Z
Acta Univ Palacki Olomuc Fac Med; 1986; 114():203-9. PubMed ID: 2946180
[No Abstract] [Full Text] [Related]
19. [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].
Huang F; Wang XL; Geng Y; Li MX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):507-9. PubMed ID: 15989803
[TBL] [Abstract][Full Text] [Related]
20. Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture.
Baylin SB; Abeloff MD; Goodwin G; Carney DN; Gazdar AF
Cancer Res; 1980 Jun; 40(6):1990-4. PubMed ID: 6245807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
